4 Healthcare Stock Stories for Wednesday Wellness
January 30, 2013
ARCA Biopharma (NASDAQ:ABIO): Current price $0.68
ARCA has supplied an update on its proposed, genetically-targeted clinical trial in atrial fibrillation of its lead developmental drug, Gencaro (bucindolol hydrochloride). The firm also reported that Medtronic has signed a non-binding Letter of Intent through which to collaborate on the initial, Phase 2B portion of the proposed trial. ARCA is a biopharmaceutical firm that is developing genetically-targeted therapies for atrial fibrillation, heart failure and other cardiovascular diseases.
Premium Newsletters
Gold & Silver
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More
Commodities Premium
There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more
ETF Investing
At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more
Wall St. Cheat Sheet has been featured in these fine media outlets:
